Q4 2024 Compass Pathways PLC Earnings Call Transcript
Key Points
- Compass Pathways PLC (CMPS) has secured financing that positions the company to complete the COMP360 program in treatment-resistant depression (TRD) and progress the PTSD development program.
- The company has recruited over 90% of patients for the 005 trial, indicating strong progress towards completing enrollment.
- Compass Pathways PLC (CMPS) is on track to report top-line results from the 005 trial in the second quarter of 2025, providing key efficacy measures.
- The recent financing provides a financial runway to fund operations through the planned 26-week data readout from the COMP006 study, expected in the second half of 2026.
- Strategic collaborations with healthcare delivery organizations are providing valuable insights into care settings, aiding in the strategy for launch and post-launch scaling.
- The company reported a net loss of $155.1 million for the year ended December 31, 2024, compared to a net loss of $118.5 million in 2023.
- Research and development expenses increased significantly to $119 million in 2024 from $87.5 million in the prior year.
- General and administrative expenses also rose to $59.2 million in 2024 from $49.4 million in the previous year.
- The company has debt under the Hercules loan facility amounting to $30.2 million at the end of the fourth quarter.
- There is uncertainty regarding the regulatory path and the specific requirements for the PTSD program, as discussions with the FDA are ongoing.
Ladies and gentlemen, thank you for standing by and welcome to the Compass Pathfinders Limited 4th quarter 2024 investor call. (Operator Instructions).I will now hand today's call over to Stephen Schultz, Senior Vice President of Investor Relations. Please go ahead, sir.
Welcome all of you and thank you for joining us today for our fourth quarter 2024 results conference call. Again, my name is Step Schultz, Senior Vice President of Investor Relations at Compass Pathways. Today I'm joined by Kabir Nath, our Chief Executive Officer, and Teri Loxam, our Chief Financial Officer, who will have prepared remarks. In addition, Dr. Guy Goodwin, our Chief Medical Officer, Lori Englebert, our Chief Commercial Officer, and Dr. Steve Levine, our Chief Patient Officer, will be available for the Q&A.
The call is being recorded and will be available on the Compass Pathways investor relations website shortly after the conclusion of the call and will be available for a period of 30 days. Before we begin, let
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
